key: cord-0839880-htdaalmm
authors: Kant, Rajni; Dwivedi, Gaurav; Zaman, Kamran; Sahay, Rima R; Sapkal, Gajanan; Kaushal, Himanshu; Nyayanit, Dimpal A; Yadav, Pragya D; Deshpande, Gururaj; Singh, Rajeev; Chaowdhary, Sandeep; Gupta, Nivedita; Kumar, Sanjay; Abraham, Priya; Panda, Samiran; Bhargava, Balram
title: Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
date: 2021-10-15
journal: J Travel Med
DOI: 10.1093/jtm/taab166
sha: c63ca21de8c0e349d6675fdbb99b85668b07eab7
doc_id: 839880
cord_uid: htdaalmm

The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.

Information on the demographic profile, vaccination history and clinical history including recent illness, co-morbidities and details of adverse events following

immunization (AEFIs) were recorded by trained investigators of the ongoing national vaccination program. The data was collected manually using paper-based forms, home visits, personal interviews and telephonic interactions and further recorded in the predesigned questionnaire.

The most common local AEFI reported after first and second vaccine dose was pain at injection site; CS (5%; 5%), CV (7.5%; 7.5%) and heterologous group (11.1%; nil 

group (Figure 1 f) . The heterologous group had ~3-fold higher titre in comparison to CS and CV groups (Figure 1 g-j) . Kruskal-Wallis test along with Dunns' multiple comparisons was performed to assess the significance in NAb titres of the sera against different SARS-CoV-2 variants.

Vaccinated individuals demonstrated higher IgG titres for the S1-RBD protein followed by N protein (Figure 1 k- 

The study was approved by the Institutional Human Ethics Committee of the ICMR- 

Full-genome sequences of the first two SARS-CoV-2 viruses from India

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised

India's role in COVID-19 vaccine diplomacy

We sincerely acknowledge the excellent support of Ms. Aasha Salunkhe, Mr. Chetan